Effect of body mass index on progesterone level on trigger day in gonadotropin-releasing hormone antagonist cycles
- PMID: 38946240
- DOI: 10.1080/09513590.2024.2364892
Effect of body mass index on progesterone level on trigger day in gonadotropin-releasing hormone antagonist cycles
Abstract
Objective: To investigate the effect of body mass index (BMI) on progesterone (P) level on trigger day in gonadotropin-releasing hormone antagonist (GnRH-ant) cycles.
Methods: This study was a retrospective cohort study. From October 2017 to April 2022, 412 in-vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) patients who were treated with GnRH-ant protocol for controlled ovarian hyperstimulation (COH) in the reproductive center of our hospital were selected as the research objects. Patients were divided into three groups according to BMI level: normal weight group (n = 230):18.5 kg/m2≤BMI < 24 kg/m2; overweight group (n = 122): 24 kg/m2≤BMI < 28 kg/m2; Obesity group (n = 60): BMI ≥ 28 kg/m2. Variables with p < .10 in univariate analysis (BMI, basal FSH, basal P, FSH days, Gn starting dose and E2 level on trigger day) and variables that may affect P level on trigger day (infertility factors, basal LH, total FSH, HMG days and total HMG) were included in the multivariate logistic regression model to analyze the effect of BMI on P level on trigger day of GnRH-ant protocol.
Results: After adjustment for confounding factors, compared with that in normal weight patients, the risk of serum P elevation on trigger day was significantly lower in overweight and obese patients (OR = 0.434 and 0.199, respectively, p < .05).
Conclusion: The risk of P elevation on trigger day in GnRH-ant cycles decreased with the increase of BMI, and BMI could be used as one of the predictors of P level on trigger day in GnRH-ant cycles.
Keywords: Body mass index (BMI); gonadotropin-releasing hormone antagonist (GnRH-ant); logistic regression; progesterone (P).
Similar articles
-
Live birth rate of gonadotropin-releasing hormone antagonist versus luteal phase gonadotropin-releasing hormone agonist protocol in IVF/ICSI: a systematic review and meta-analysis.Expert Rev Mol Med. 2023 Dec 14;26:e2. doi: 10.1017/erm.2023.25. Expert Rev Mol Med. 2023. PMID: 38095077 Free PMC article. Review.
-
Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels.Taiwan J Obstet Gynecol. 2021 Jul;60(4):739-744. doi: 10.1016/j.tjog.2021.05.027. Taiwan J Obstet Gynecol. 2021. PMID: 34247817
-
Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.Cochrane Database Syst Rev. 2014 Oct 31;2014(10):CD008046. doi: 10.1002/14651858.CD008046.pub4. Cochrane Database Syst Rev. 2014. PMID: 25358904 Free PMC article. Review.
-
[Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].Zhonghua Fu Chan Ke Za Zhi. 2012 Apr;47(4):245-9. Zhonghua Fu Chan Ke Za Zhi. 2012. PMID: 22781108 Chinese.
-
Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles.Gynecol Endocrinol. 2007 Jun;23(6):338-42. doi: 10.1080/09513590701403629. Gynecol Endocrinol. 2007. PMID: 17616858
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
